These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 26859662)

  • 1. The Case for Reforming Drug Naming: Should Brand Name Trademark Protections Expire upon Generic Entry?
    Sarpatwari A; Kesselheim AS
    PLoS Med; 2016 Feb; 13(2):e1001955. PubMed ID: 26859662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Product-line extensions and pricing strategies of brand-name drugs facing patent expiration.
    Hong SH; Shepherd MD; Scoones D; Wan TT
    J Manag Care Pharm; 2005; 11(9):746-54. PubMed ID: 16300418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategic options for brand-name prescription drugs when patents expire.
    Mehta SC; Mehta SS
    Health Mark Q; 1997; 14(3):107-14. PubMed ID: 10167309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of generic competition on the price of brand-name drugs.
    Lexchin J
    Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Competition in prescription drug markets: the roles of trademarks, advertising, and generic names.
    Feldman R; Lobo F
    Eur J Health Econ; 2013 Aug; 14(4):667-75. PubMed ID: 22815099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reference pricing of pharmaceuticals.
    Brekke KR; Königbauer I; Straume OR
    J Health Econ; 2007 May; 26(3):613-42. PubMed ID: 17188769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selling Patents to Indian Tribes to Delay the Market Entry of Generic Drugs.
    Ablavsky G; Larrimore Ouellette L
    JAMA Intern Med; 2018 Feb; 178(2):179-180. PubMed ID: 29297039
    [No Abstract]   [Full Text] [Related]  

  • 8. Longer patents for increased generic competition in the US. The Waxman-Hatch Act after one decade.
    Grabowski H; Vernon J
    Pharmacoeconomics; 1996; 10 Suppl 2():110-23. PubMed ID: 10163428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prices, profits, and innovation: examining criticisms of new psychotropic drugs' value.
    Huskamp HA
    Health Aff (Millwood); 2006; 25(3):635-46. PubMed ID: 16684726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent trends in brand-name and generic drug competition.
    Grabowski H; Long G; Mortimer R
    J Med Econ; 2014 Mar; 17(3):207-14. PubMed ID: 24320785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategies That Delay Market Entry of Generic Drugs.
    Vokinger KN; Kesselheim AS; Avorn J; Sarpatwari A
    JAMA Intern Med; 2017 Nov; 177(11):1665-1669. PubMed ID: 28975217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in the Number of Continuation Patents on Drugs Approved by the FDA.
    Tu SS; Kesselheim AS; Wetherbee K; Feldman WB
    JAMA; 2023 Aug; 330(5):469-470. PubMed ID: 37526728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brand-name drug manufacturers risk antitrust violations by slowing generic production through patent layering.
    Paine CS
    Seton Hall Law Rev; 2003; 33(2):479-510. PubMed ID: 12715807
    [No Abstract]   [Full Text] [Related]  

  • 14. The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms.
    Panattoni LE
    J Health Econ; 2011 Jan; 30(1):126-45. PubMed ID: 21074873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Discount for only one drug of the same group leads to impaired health care quality].
    Bergström R
    Lakartidningen; 2006 Feb 8-14; 103(6):387-8; discussion 388. PubMed ID: 16536044
    [No Abstract]   [Full Text] [Related]  

  • 16. Reference pricing with endogenous generic entry.
    Brekke KR; Canta C; Straume OR
    J Health Econ; 2016 Dec; 50():312-329. PubMed ID: 27350294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using a drug-safety tool to prevent competition.
    Sarpatwari A; Avorn J; Kesselheim AS
    N Engl J Med; 2014 Apr; 370(16):1476-8. PubMed ID: 24738666
    [No Abstract]   [Full Text] [Related]  

  • 18. Competition between brand-name and generics--analysis on pricing of brand-name pharmaceutical.
    Kong Y
    Health Econ; 2009 May; 18(5):591-606. PubMed ID: 18816580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generics battle brand names over mortality of drug patents.
    Betz R
    J Healthc Resour Manag; 1995 Jul; 13(7):35-7. PubMed ID: 10144008
    [No Abstract]   [Full Text] [Related]  

  • 20. Interrupted time-series analysis of the impact of generic market entry of antineoplastic products in China.
    Guan X; Tian Y; Ross-Degnan D; Man C; Shi L
    BMJ Open; 2018 Jul; 8(7):e022328. PubMed ID: 30012792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.